NCT05442749 2026-02-17
PARPi-PANC
Centre Leon Berard
Phase 2 Terminated
Clinical Trials
14 trialsNCT04779151 2025-12-01
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated
NCT04159155 2025-08-12
CAN-STAMP
University Health Network, Toronto
Phase 2/3 Terminated
NCT04926324 2025-06-29
A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers
University of Iowa
Phase 1/2 Terminated
NCT05297864 2025-05-23
OU-SCC-PI-4G
University of Oklahoma
Phase 2 Terminated
NCT05523440 2025-03-28
Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
University of Oklahoma
Phase 2 Terminated
NCT03891576 2025-01-17
Newton
Mario Negri Institute for Pharmacological Research
Phase 2 Terminated
NCT04826198 2024-12-05
REVOCAN
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Terminated
NCT03644342 2024-09-03
NIVIX
Baylor College of Medicine
Phase 1/2 Terminated
NCT03840967 2024-06-04
A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03209401 2024-02-05
Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies
Georgetown University
Phase 1 Terminated
NCT03944902 2023-11-21
BRCA
University of Alabama at Birmingham
Phase 1 Terminated
NCT02826512 2022-07-18
A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients
The Netherlands Cancer Institute
Phase 2 Terminated
NCT02500901 2019-10-21
Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)
Hoosier Cancer Research Network
Phase 1 Terminated